D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities

被引：0
|
作者：
Zhang, Jing
Lim, Sun Min
Yu, Mi Ra
Chen, Cheng
Wang, Jia
Wang, Wenqian
Rui, Haopeng
Lu, Jingtao
Lu, Shun
Mok, Tony
Chen, Zhi Jian
Cho, Byoung Chul
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6503
引用
收藏
页数：2
相关论文
共 8 条
  • [1] D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
    Zhang, Jing
    Lim, Sun Min
    Yu, Mi Ra
    Chen, Cheng
    Wang, Jia
    Wang, Wenqian
    Rui, Haopeng
    Lu, Jingtao
    Lu, Shun
    Mok, Tony
    Chen, Zhi Jian
    Cho, Byoung Chul
    CANCER DISCOVERY, 2024, 14 (09) : 1675 - 1698
  • [2] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
    Cho, Byoung Chul
    Lu, Shun
    Lee, Myung Ah
    Song, Zhengbo
    Park, John
    Lim, Sun Min
    Li, Ziming
    Zhao, Jun
    Richardson, Gary
    Zhang, Yanqiao
    Zhang, Jun
    Liu, Anwen
    Chen, Cheng
    Wang, Jia
    Lu, Jingtao
    Rui, Haopeng
    Chen, Qian
    Wang, Hui
    Zhang, Jing
    Chen, Zhi Jian
    Mok, Tony
    CANCER RESEARCH, 2024, 84 (07)
  • [3] Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
    Cho, B. C.
    Lu, S.
    Lee, M. A.
    Song, Z.
    Park, J. J. W.
    Lim, S. M.
    Li, Z.
    Zhao, J.
    Richardson, G.
    Zhang, Y.
    Zhang, J.
    Liu, A.
    Chen, C.
    Wang, J.
    Chen, J.
    Wang, A.
    Zhang, J.
    Chen, Z. G.
    Mok, T. S. K.
    Johnson, M. L.
    ANNALS OF ONCOLOGY, 2024, 35 : S493 - S493
  • [4] Preclinical characterization of D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C.
    Zhang, Jing
    Wu, Wentao
    Xu, Yangyang
    Qian, Yi
    Xia, Yuanfeng
    Lu, Jiang
    Zheng, Zhiqiang
    Lu, Jingtao
    Chen, Janet
    Chen, Chase
    Wang, Jia
    Chen, Cheng
    Rui, Haopeng
    Wang, Allison
    Jin, John
    Chen, Zhi Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagement kinetics
    Zhang, J.
    Lu, J.
    Zheng, Z.
    Lu, J.
    Wang, A.
    Wang, J.
    Chen, J.
    Rui, H.
    Chen, C.
    Chen, G.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S74 - S74
  • [6] D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C: Human dose prediction and first-in-human (FIH) trial design.
    Lu, Jingtao
    Zhang, Jing
    Zheng, Zhiqiang
    Chen, Cheng
    Wang, Jia
    Chen, Janet
    Lu, Jiang
    Rui, Haopeng
    Wang, Allison
    Chen, Zhi Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Combination of D3L-002, an anti-TIGIT/PVRIG bispecific antibody, with D3S-001, a KRAS G12C inhibitor, transformed tumor microenvironment from cold to hot and achieved durable tumor remission in preclinical models
    Chen, George
    Zhang, Jing
    Rui, Haopeng
    Yang, Xiaofeng
    Wang, Tienan
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [8] Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation
    Cho, B. C.
    Shen, Y.
    Li, Z.
    Lu, S.
    Lee, M. A.
    Song, Z.
    Park, J. J. W.
    Lim, S. M.
    Zhao, J.
    Richardson, G.
    Zhang, Y.
    Zhang, J.
    Liu, A.
    Chen, C.
    Liu, Y.
    Rui, H.
    Chen, J. Q.
    Wang, A. H.
    Zhang, J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1642 - S1643
1